Home banner
Divider
A-Z Index

Quick way to the find the information that you need...

More button
Register with FRAME

Although you do not need to register, any information you provide will be confidential and used only by FRAME to improve the website

Register button
Account Login
Forgot password?

ATLA - ISI
The Journal

 

Alternatives to Laboratory Animals - ATLA

Download latest issue button Download back issues button Subscribe to ATLA
Contact Us

Tel icon

Tel: +44 (0)115 9584740


Tel icon

Fax: +44 (0)115 9503570

Make an Enquiry

Book Chapter References

In: Implant Dentistry Research Guide: Basic, Translational and Experimental Clinical Research (ed. Ahmed Ballo). Nova Science Publishers, Inc., Hauppauge, NY, USA.


Ethics and Regulation in the Use of Laboratory Animals
Michelle Hudson and Michael Balls

Balls M. Scientific procedures on living animals: Proposals for reform of the 1876 Cruelty to Animals Act. Altern Lab Anim. 1985;12:225-42. PDF

 

Balls M, Clothier R. A FRAME response to the European Commission Consultation on the Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects — 2010. Altern Lab Anim. 2010; 38:345-53.  PDF


Bérubé K, Aufderheide M, Breheny D, Clothier R, Combes R, Duffin et al. In vitro models of inhalation toxicity and disease. Altern Lab Anim. 2009;37:89-141. PDF


Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern Lab Anim. 2006;34:225–39.  PDF


Brown MJ, White WJ. Reflections on improved health status of rodents bred for research: Contributions to the reduction and refinement of animal use. Altern Lab Anim. 2009;37:187-9. PDF


Combes R, Balls M, Illing P, Bhogal N, Dale J, Duvé G et al. Possibilities for a new approach to chemicals risk assessment. Altern Lab Anim. 2006;34:621-49.PDF


Combes RD, Gaunt I, Balls M. A scientific and animal welfare assessment of the OECD Health Effects Test Guidelines for chemicals under the EU REACH system. Altern Lab Anim. 2004;32:163-208.  PDF


Curwen JO, Wedge SR. The use and refinement of rodent models in anti-cancer drug discovery: a review. Altern Lab Anim. 2009;37:173-80. PDF


Festing MFW. Fifty years after Russell and Burch, toxicologists continue to ignore genetic variation in their test animals. Altern Lab Anim. 2009;37:1-5. PDF


Festing MFW, Baumans V, Combes RD, Halder M, Hendriksen CFM., Howard BR, et al. Reducing the use of laboratory animals in biomedical research: problems and possible solutions. Altern Lab Anim. 1998;26:283-301. PDF

 

Gaines Das R, Fry D, Preziosi R, Hudson M. Planning for reduction. Altern Lab Anim. 2009;37:27-32. PDF

 

Holden AV. Development and application of human virtual excitable tissues and organs: from premature birth to sudden cardiac death. Altern Lab Anim. 2010;38,suppl.1:87-99.  PDF


Honess P, Wolfensohn S. The extended welfare assessment grid: a matrix for the assessment of welfare and cumulative suffering in experimental animals. Altern Lab Anim. 2010;38:205-12. PDF


Hooijmans CR, Leenaars M, Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic review more feasible. Altern Lab Anim. 2010;38:167-82. PDF


Howard B, Hudson M, Preziosi R. More is less: Reducing animal use by raising awareness of the principles of efficient study design and analysis. Altern Lab Anim. 2009;37:33-42. PDF


Jennings M. Refinement: A sense of progress. Altern Lab Anim. 2009;37:149-53. PDF


Kleiman M, Sagi Y, Bloch N, Agur Z. Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials. Altern Lab Anim. 2009;37,suppl.1:39-45. PDF


Knight A, Bailey J, Balcombe J. Animal carcinogenicity studies: 2. obstacles to extrapolation of data to humans. Altern Lab Anim. 2006;34:29-38.  PDF


 
In: New Technologies for Toxicity Testing (ed. Michael Balls, Robert Combes & Nirmala Bhogal). Landes Biosciences/Springer Science+Business Media, Austin, TX, USA.


Foreword and Introduction
Robert D. Combes, Michael Balls and Nirmala Bhogal

In progress.


In Silico Methods for Toxicity Prediction
Robert D. Combes

In progress.


The Use of Integrated and Intelligent Testing Strategies in the Prediction of Toxic Hazard and in Risk Assessment
Michael Balls, Robert D. Combes and Nirmala Bhogal

Aithal GP. Mind the gap. Altern Lab Anim—ATLA 2010; 38(suppl. 1):1–4. PDF


Balls M. (2011) Modern alternative approaches to the problem of drug-induced liver injury. Altern Lab Anim—ATLA 2011; 39:103–107. PDF


Balls M, Clothier R. A FRAME Response to the European Commission Consultation on the Draft Report on Alternative (Nonanimal) Methods for Cosmetics Testing: Current Status and Future Prospects—2010. Altern Lab Anim—ATLA 2010; 38(5):345–353. PDF


BéruBé K. Alternatives for lung research: stuck between a rat and a hard place. Altern Lab Anim—ATLA 2011; 39(2):121–130. PDF


BéruBé K, Aufderheide M, Breheny D et al. In vitro models of inhalation toxicity and disease. The Report of a FRAME Workshop. Altern Lab Anim—ATLA 2009; 37(1):89–141. PDF


Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern Lab Anim—ATLA 2006; 34(2):225–239. PDF


Combes R, Balls M. Intelligent testing strategies for chemicals testing—A case of more haste, less speed? Altern Lab Anim—ATLA 2005; 33(3):289–297. PDF


Combes RD, Balls M. Integrated testing strategies for toxicity employing new and existing technologies. Altern Lab Anim—ATLA 2011; 39(3):213–225. PDF


Combes RD, Gaunt I, Balls M. (2004). A scientific and animal welfare assessment of the OECD health effects test guidelines for the safety testing of chemicals under the European Union REACH system. Altern Lab Anim—ATLA 2004; 32(3):163–208.  PDF

 

Combes R, Grindon C, Cronin, MTD et al. Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. Altern Lab Anim—ATLA 2007; 35(2):267–287. PDF


Combes R, Grindon C, Cronin MTD et al. Integrated decision-tree testing strategies for acute systemic toxicity and toxicokinetics with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2008; 36(1):45–63. PDF


Doehmer J. The use and value of in vitro technologies in metabolism studies. Altern Lab Anim—ATLA 2009; 37(suppl. 1):29–32. PDF


Grindon C, Combes R, Cronin MTD et al. Integrated testing strategies for use in the EU REACH system. Altern Lab Anim—ATLA 2006; 34(4):407–427. PDF


Grindon C, Combes R, Cronin MTD et al. Integrated decision-tree testing strategies for skin corrosion and irritation with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2007; 35(6):673–682. PDF


Grindon C, Combes R, Cronin MTD et al. An integrated decision-tree testing strategy for skin sensitisation with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2007; 35(6):683–697.  PDF


Grindon C, Combes R, Cronin MTD et al. Integrated decision-tree testing strategies for developmental and reproductive toxicity with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2008; 36(1):65–80. PDF


Grindon C, Combes R, Cronin MTD et al. An integrated decision-tree testing strategy for eye irritation with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2008; 36(1):81–92. PDF


Grindon C, Combes R, Cronin MTD et al. An integrated decision-tree testing strategy for repeat dose toxicity with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2008; 36(1):93–101. PDF


Grindon C, Combes R, Cronin MTD et al. Integrated decision-tree testing strategies for environmental toxicity with respect to the requirements of the EU REACH legislation. Altern Lab Anim—ATLA 2008; 36(suppl. 1):29–42.   PDF

 

Holden AV. Development and application of human virtual excitable tissues and organs from premature birth to sudden cardiac death. Altern Lab Anim—ATLA 2010; 38(suppl. 1):87–99. PDF


Kinsner-Ovaskainen A, Akkan Z, Casati S et al. (2009). Overcoming barriers to validation of non-animal partial replacement methods/integrated testing strategies: The Report of an EPAA–ECVAM Workshop. Altern Lab Anim—ATLA 2009; 37(4):437–444. PDF


Kleiman M, Sagi Y, Bloch N et al. (2009) Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials. Altern Lab Anim—ATLA 2009; 37(suppl. 1):39–45.  PDF


Knight A, Bailey J, Balcombe J. Animal carcinogenicity studies: 2. Obstacles to extrapolation of data to humans. Altern Lab Anim—ATLA 2006; 34(1):29–38. PDF


Mandenius CF, Andersson TB, Alves PM et al. Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines—a report on the Vitrocellomics EU-project. Altern Lab Anim—ATLA 2011; 39:147–171. PDF


Thomas S. Physiologically-based simulation modelling for the reduction of animal use in the discovery of novel pharmaceuticals. Altern Lab Anim—ATLA 2009; 37(5):497–511. PDF


 
In: Pharmaceutical Biotechnology — A Comprehensive Handbook (ed. Oliver Kayser & Heribert Warzecha). Wiley-VCH, Weinheim, Germany.


Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application — and Back Again
Michael Balls, Andrew Bennett and David Kendall

 

Aithal GP. Mind the gap. ATLA 2010; 38(suppl. 1):1–4. PDF


Balls M. Modern Alternative Approaches to the Problem of Drug-induced Liver Injury. ATLA 39, 103–107, 2011. PDF


Baxter GT. Hurel™ — an In Vivo-surrogate Assay Platform for Cellbased Studies. ATLA 37, Supplement 1, 11–18, 2009 PDF


BeruBe K, et al. In Vitro Models of Inhalation Toxicity and Disease The Report of a FRAME Workshop. ATLA 37, 89–141, 2009. PDF


Boyer S. The Use of Computer Models in Pharmaceutical Safety Evaluation. ATLA 37, 467–475, 2009. PDF


Coleman RA. A Human Approach to Drug Development: Opportunities and Limitations. ATLA 2010; 38(suppl. 1):21-25. PDF


Combes R, et al. Possibilities for a New Approach to Chemicals Risk Assessment — The Report of a FRAME Workshop. ATLA 34, 621–649, 2006. PDF


Combes R, Barratt M and Balls M. An Overall Strategy for the Testing of Chemicals for Human Hazard and Risk Assessment under the EU REACH System. ATLA 31, 7–19, 2003. PDF


Combes R and Balls M. Integrated Testing Strategies for Toxicity Employing New and Existing Technologies. ATLA 39, 213–225, 2011. PDF


Cronin MTD, Bajot F, Enoch SJ, Judith C, Madden JC, Roberts DW and Schwöbel J. The In Chemico–In Silico Interface: Challenges for Integrating Experimental and Computational Chemistry to Identify Toxicity. ATLA 2009; 37(5) 513–521.  PDF


Cronin MTD. In Silico Toxicology Challenges for Pharmaceuticals: Complacency or Controversy? ATLA 2009; 37 (5), 453–456. PDF


Doehmer J. The Use and Value of In Vitro Technologies in Metabolism Studies. ATLA 2009; 37(suppl. 1):29-32. PDF


Enoch SJ, Cronin MTD and Ellison C. The Use of a Chemistry-based Profiler for Covalent DNA Binding in the Development of Chemical Categories forRead-across for Genotoxicity. ATLA 39, 131–145,2011.  PDF


Hardingham T. Cell- and Tissue-based Approaches for Cartilage Repair. ATLA 38, Supplement 1, 35–39, 2010. PDF


Higbee RG et al. An Immunologic Model for Rapid Vaccine Assessment — A Clinical Trial in a Test Tube. ATLA 37, Supplement 1, 19–27, 2009. PDF 


Holden AV. Development and application of human virtual excitable tissues and organs from premature birth to sudden cardiac death. ATLA 2010; 38(suppl. 1):87–99. PDF


Holliday DL. A Three-dimensional In Vitro Model of Breast Cancer: Toward Replacing the Need for Animal Experiments. ATLA 38, Supplement 1, 41–44, 2010 PDF


Kleiman M, Sagi Y, Bloch N and Agur Z. Use of Virtual Patient Populations for Rescuing Discontinued Drug Candidates and for Reducing the Number of Patients in Clinical Trials. ATLA 37, Supplement 1, 39–45 2009. PDF

 

Li AP. The Use of the Integrated Discrete Multiple Organ Coculture (IdMOC®) System for the Evaluation of Multiple Organ Toxicity. ATLA 37, 377–385, 2009. PDF


Mandenius CF et al. Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project. ATLA 39, 147–171, 2011. PDF


Stephens P. Development of a Cell-based Diabetic Wound Assay. ATLA 38, Supplement 1, 45–48, 2010. PDF


Thomas S. Physiologically-based Simulation Modelling for the Reduction of Animal Use in the Discovery of Novel Pharmaceuticals. ATLA 37, 497–511, 2009. PDF


Trigwell S. (Ed). The FRAME/Liverpool John Moores University/Defra REACH Project. ATLA 36, Supplement 1. 2008.  PDF (very large file)


Tsaioun K and Jacewicz M. De-Risking Drug Discovery with ADDME — Avoiding Drug Development Mistakes Early. ATLA 37, Supplement 1, 47–55, 2009. PDF


Vedani A and Smiesko M. In Silico Toxicology in Drug Discovery — Concepts Based on Three-dimensional Models. ATLA 37, 477–496, 2009.  PDF


Wills Q and Mitchell C. Toxicogenomics in Drug Discovery and Development —Making an Impact. ATLA 37, Supplement 1, 33–37, 2009. PDF


Worth AP and Balls M. The Importance of the Prediction Model in the Validation of Alternative Tests. ATLA 29, 135–143, 2001. PDF